Navigation Links
Vitek 2 - XL

ProductsVitek 2 - XL
Company bioMerieux, Inc.
Item Vitek 2 - XL
Features Reduced time for identification and antibiotic susceptibility results, offer an extensive analysis menu, miniaturized card-format consumable (10 cm x 6 cm x 0.5 cm) consisting of 64 wells, fluorescent technology, fast reports, advanced expert system, automated functions.
Description The Vitek 2 - XL is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacterial resistance.
Info bioMerieux, Inc.
Customer Service: (800) 682-2666
Web site: http://www.biomerieux-usa.com

Related medicine products :

1. Vitek
2. Vitek 2
TAG: Vitek
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades.
This is a perfect tool for retrieving free floating sections from the Vibratome bath.
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray.
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi
Medicine Products:
(Date:11/21/2008)... Barr Pharmaceuticals, In...lders overwhelmingly approved the proposals submit... Teva Pharmaceuticals Industries Ltd. (Nasdaq: T...overwhelming support of the transaction by the Bar...rman and CEO. "We are pleased with the progress th...
(Date:11/21/2008)... deadly diseaseits cause remains a mysteryswept in... with citizens, soldiers and refugees of the war t...illed with corpses, social order broke down. Over ...nd Athens lost a third of its population. It lost ...ning of the end of the Golden Age of Greece. , ...
(Date:11/21/2008)... 21 A prestigious group of physici...gather in Williamsburg, VA on March 27-29, 2009 at...al information on cutting-edge therapeutic protoco...search advances that impact patient care. The full... information is available at www.bioconferences.c...
(Date:11/21/2008)...use is more prevalent and smoking cessation less l...tivity Disorder (A.D.H.D.) In a study of smokers ... those who exhibited elevated hyperactivity and im...er quit rates after 8 weeks than those with inatte... symptoms. The study, now available online in Ni...
Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...leadership in the companion fields of stem cell re...of Wisconsin-Madison will establish a new Stem Cel...ent of the new center, to be made today (May 17) a...ental biologist Ian Wilmut, the creator of the clo...
...uffer in silence, cough up more money to get thing...lts. And here comes the news that a hospital grou...its workmanship, charging a flat fee that includes...nt. Even if a patient suffers complications or ha...
...are, Dr. David Parirenyatwa, says that the illegal...verely compromised the country's health delivery ... World Health Assembly in Geneva, Switzerland, to ...onditional lifting of these sanctions. He calls t...
... response to numerous complaints over local health...tient clinic in Evansville city that would open b...ut 87,000 square feet that must be available for o...l veterans have complained for nearly two years ab...
Other Medicine News:Health News:UW Establishes Stem Cell and Regenerative Medicine Center 2Health News:US Hospital Group Offers Warranty on Surgeries 2Health News:US Hospital Group Offers Warranty on Surgeries 3Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2
(Date:11/20/2008)...mber 20 Arpida (SWX:,AR...Advisory Committee of the,U.S. Food and Drug Admi...proval of intravenous iclaprim, an antibiotic curr...s with complicated skin and skin structure infecti...in-resistant Staphylococcus,aureus (MRSA). , ...
(Date:11/20/2008)... -- Clinical data from a prospective,registry pre...m shows DVT,treatment with the Trellis(R) Periphe...Santa Clara, CA) successfully breaks up the blood ... This technique, called isolated pharmacomechani...y and safely than current catheter-directed thromb...
(Date:11/19/2008)...eve statistical significance , , ISELIN, N....poration (Nasdaq: PARS ) today announced results...anoEmulsion (NE) drug delivery technology formulat...he multi-center, randomized, double-blinded, place...acy of the Company,s 3% Diclofenac Diethanolamine ...
(Date:11/18/2008)...e-FirstCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a ...evelopment Company,and Sosei Group Corporation (...rnational biopharmaceutical company, today announc...al pre-clinical efficacy data for NSL-043/SD118.,...or neuropathic pain and has,successfully complete...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Nicotine Plus Alcohol May Be Tough to Beat 5651 1Nicotine Plus Alcohol May Be Tough to Beat 5651 2Nicotine Plus Alcohol May Be Tough to Beat 5651 3AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 1AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 2Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases 771 1Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases 771 2MicroActive Corporation Acquired by Linden and Edgewater 5649 1MicroActive Corporation Acquired by Linden and Edgewater 5649 2
...ies Presented at ECCMID/ICC, MUNICH, Germany, Apri...oday announced results from two studies showing th...l growth in vitro,when tested with a common wettin...ng the activity of oritavancin against S.,pneumoni...ovel,lipoglycopeptide antibiotic, is Targanta,s le...
...rBChE Suppresses Amyloid Plaque,Formation , ANNAPO...ding,biodefense company specializing in the develo...ures against chemical and,biological terrorism, an...utyrylcholinesterase (rBChE) research program were...rence on,Alzheimer,s and Parkinson,s Diseases in S...
Other Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6